JPMorgan lowers Relay Therapeutics' target price to $23, citing negative EPS and insider trading.

JPMorgan Chase & Co. and several other firms have lowered Relay Therapeutics' (NASDAQ: RLAY) target prices, with JPM reducing its target from $29.00 to $23.00. Analysts expect negative earnings per share for the current year and insider trading activity has been observed. These adjustments follow recent reports with various price objectives and ratings. Large institutional investors have also made changes to their holdings of Relay Therapeutics shares.

August 11, 2024
3 Articles